Thursday, January 26, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Defense + Military

DoD Awards 35M Adenovirus Vaccine Contract

by Global Biodefense Staff
June 3, 2016
DoD Adenovirus Vaccine

Oral adenovirus vaccine tablets. Image credit: U.S. Army Medical Materiel Development Activity

DoD Adenovirus Vaccine
Oral adenovirus vaccine tablets. Image credit: U.S. Army Medical Materiel Development Activity

The Adenovirus vaccine has been protecting military trainees from infections by Adenovirus serotypes 4 and 7 since October 2011, when the military services resumed its use after a 12-year gap.

Back in 2001, Barr entered into a multi-year agreement with the U.S. Department of Defense (DOD) for clinical development of the Adenovirus Vaccines, Type 4 and 7. As part of the agreement, Barr constructed a dedicated facility to support the production of supplies necessary to complete the approval process and support projected needs of the DOD. The company completed the Phase I study in April 2006, and completed the Phase III clinical program in April 2008.

See also: Restoring Adenovirus Vaccine (Contract Pharma)

The finished dosage form is an orally administered enteric-coated tablet, with an inner tablet core containing live adenovirus — type 4 or type 7 — surrounded by an outer tablet coat and a final enteric coating. The vaccines are administered as individual oral tablets taken together.

The DoD this week awarded Barr Laboratories Inc., a subsidiary of Teva Pharmaceutical Industries Ltd., in North Wales, Pennsylvania, a maximum $35,232,541 modification (P00005) exercising the second one-year option period of a one-year base contract (SPE2DP-15-D-0002) with four one-year option periods for continued supply of these two types of adenovirus vaccine.

This is a firm-fixed-price contract with a Dec. 31, 2017, performance completion date. The contracting activity is the Defense Logistics Agency Troop Support, Philadelphia, Pennsylvania.

Read more: Protein Sciences Awarded DoD Grant for Novel Adenovirus Vaccine

Surveillance data provided by the Naval Health Research Center shows the Adenovirus vaccine is 99 percent effective at preventing disease associated with Adenovirus type 4. Since October 2011, the use of the vaccine by the DoD has prevented an estimated 50,000 cases of Febrile Respiratory Illness, saving roughly 150,000 training days that would have been lost to illness.

Tags: AdenovirusAwardsVaccines

Related Posts

DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
How Are Bivalent COVID Vaccines Stacking Up Against Omicron?
Infectious Diseases

How Are Bivalent COVID Vaccines Stacking Up Against Omicron?

January 12, 2023
NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies
Medical Countermeasures

NISTCHO: New Living Reference Material for Producing Monoclonal Antibodies

January 12, 2023
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC